Good afternoon, John Block with Stifel, and happy to introduce SofWave, who we have back again this year. Their CFO, Assaf Korner. I think for you guys who aren't that familiar with SofWave, they're really executing in aesthetics. It's a razor-razor blade platform. The blade or the recurring continues to increase as a percent of revenue, and we were just catching up earlier, they just put up, I think it was their sixth consecutive profitable quarter. So really combining top-line growth with profitability, and again, aided by that higher margin recurring. I'm going to turn it over to Assaf for some more details. We'll go through some slides, and then we'll save some time at the end for some Q&A.
Sounds good. Thank you, John, and good afternoon, everybody. This presentation is covered by safe harbor regulations, so please take a second to look at the disclaimer. SofWave Medical is an aesthetic medical equipment company with patented protected proprietary ultrasound beam technology for safe, non-invasive head, neck, and body skin regeneration. We have a broad range of 12 FDA clearances, all the way from lifting, laxity, and wrinkle treatment on the face, the neck, and the body. We also have a unique EMS technology, muscle stimulation technology, for muscle toning. We have a strong revenue growth trajectory. We just released our Q3 2026 numbers last week. Our revenue grew 35% year-over-year in the third quarter. Our CAGR from 2021 to 2025 grew by 42%. We have a superior treatment model and ROI for our clinicians.
John touched a little bit about it, but we enjoy the sale of the capital equipment to the clinician, but then we take a small piece of every treatment that is being done, and this is our utilization fee that continue to grow. Actually, last quarter, 47% of our revenue did not come from selling per se just the capital equipment, but from selling treatments or physicians doing treatments with our devices. We are a global company. We are growing internationally and globally. Over 50% of our revenue in the third quarter were outside of the U.S., and we just got a very exciting approval from the NMPA. NMPA is the Chinese FDA. Very exciting about the opportunity to start selling in China. We're a publicly traded company on the Tel Aviv Stock Exchange. We reported that we installed, sold approximately 3,400 SofWave systems in over 50 countries.
Few more highlights of the third quarter . So revenue for the third quarter hit $28.5 million, represents a 35% year-over-year growth. We have a very solid and healthy gross margin of over 76%. One interesting thing about our consumable per se is that it's a completely virtual consumable. It's like selling a software code. It counts, it's almost 100% gross margin. So while we have a very healthy gross margin on the device, on the capital equipment, we have almost 100% gross margin on the consumable. That support is of a very strong gross margin. Utilization fee, the usage fee in the third quarter grew up to $13.3 million, grew 60% year-over-year. This is basically the utilization fee and the recurring revenue, and that represent, as I said, 47% of our revenue.
We posted an all-time high net income, $4.6 million net income on a non-IFRS basis. That is including stock-based compensation. We installed 3,400 systems. We performed over 1.1 million treatments. We can estimate the number of treatments based on the utilization, and we crossed the million treatments in the third quarter . We have a very strong cash position. We generate cash. We generated $2.6 million in the third quarter , and we have $41.4 million on the balance sheet as of the end of September. A few more highlights about the third quarter financials. First of all, on the left-hand side, on the graph, we can see the revenue coming from the utilization of the device. As I said, they hit $13.3 million. There is a little bit of the Q3 seasonality, but if we can look at it is really modest comparing.
Considering the fact that July and August are very slow in business generally, and especially in aesthetic, when people mainly vacation and go to the beach, they do less aesthetic treatments, we still were able to grow our recurring revenue and utilization by 60% to $13.3 million. We see how it grew from $5.5 million only two years ago. 47% were on a recurring basis of 17.2% of our operating margin, growing up from 8.9% in the third quarter of 2025. We are not only growing on the utilization of the device, we also grew by 19% on selling the capital equipment, selling the boxes themselves. A few words about the people behind the company. Our Chairman and Co-Founder, Dr. Shimon Eckhouse, is considered to be one of the founding fathers of the aesthetic medical device industry.
He is the founder of Lumenis, a company that was established in the 1990s. He is the Co-Founder of what we know today as Syneron and Candela, founded at the beginning of 2000, 2001. This is the third large public company that Shimon is actually starting in the field of aesthetics. Beside of that, he is a well-known entrepreneur in Israel with dozens of companies in his portfolio and his career. He is the inventor of the IPL, and he has over 100 patents registered under his name. Lou Scafuri, our CEO, is not here today, but he has been in the space for over 25 years. He was in the leading position at Lumenis together with Shimon. He was then the CEO of Syneron and Candela, one of the largest companies in the space.
He has been with the company for seven years, and we are very lucky to have somebody like Lou leading a company like SofWave. I have been in the space in biotechnology and medical device for over 20 years, over 15 of them in aesthetic. I spent over 10 years at Syneron and Candela, and now over five years in SofWave, sorry. I am not going to go name by name here on the slide, but everybody here has long-term experience in aesthetic medicine. A little bit about the space and what we see. We see the medical aesthetic space entering what we see as a multi-year structural expansion. We see four main drivers that are creating this structural expansion in the space. First of all, we see a conversion patient group. We see new patient groups that were not in the space before. First and foremost, GLP-1 patients.
Until a few years ago, nobody knew exactly what GLP-1 was. But now there's data out there that one out of eight adult Americans either are on GLP-1 or used GLP-1 in the past. The numbers are probably bigger than that. These patients, the GLP-1 patients who lose a lot of weight and lose it fast and relatively safely, need two main things. They need skin tightening, because when you lose a lot of fat, you lose volume on your face, on your neck, and on your body, and you need to tighten the skin. You also need to strengthen your muscles. Many people do not know, but when you lose a lot of fat, you lose a lot of weight, you don't lose only fat, you lose only muscle.
The weight that you lose or the stress that you lose for the muscles needs to be stressed either by exercise or by equipment such as ours. In addition to this, we see a growing population of menopause and the longevity patients. People are talking about longevity. It's everywhere. Combination of a protocol, be stronger, live longer, wellness, and the long-term engagement with companies continue to grow. We see consumer brand loyalty. We see consumers being more and more aware of brands, and we build a brand here that we want patients to ask for the SofWave treatment from the physicians. Since we install the system, we sell the system, and then we enjoy the utilization of the system, we invest a lot in marketing and building a brand that patients will ask clinicians for the SofWave treatment. We see a trend of natural regeneration.
Patients today want natural-looking outcomes. They want minimal downtimes, which is exactly what we perform with our SofWave device. The comfort is really, really important for them. All this is translating to an expanding treatment option market that is growing from approximately $63 billion in 2024 at a 9% CAGR to $97 billion in 2029. A few words about our technology. We do skin tightening and skin rejuvenation completely non-invasively while protecting the epidermis. We have proprietary ultrasound technology that know how to generate heat in the mid-dermis, go through the epidermis without damaging the epidermis at all, into the mid-dermis in order to create a controlled injury in the mid-dermis. This controlled injury cause our body to regenerate again collagen and elastin that our body is slowing down in producing as we grow older.
These are the two components in the mid-dermis that makes our skin looks younger, tighter, and brighter. Not only that we create this thermal injury in the mid-dermis layer, we also do it, first of all, non-invasively, as I said, but we're protecting the epidermis with proprietary cooling technology. Here on the slide, you can see the head of the applicator with the seven ultrasound transducers. If you put your hand on the applicator, it's actually cold. So we are cooling the epidermis while shooting the ultrasound energy into the mid-dermis. So we're creating a non-invasive, very safe treatment, very comfortable for the patient, and also comfortable for the clinician. It can be delegated to almost everybody within the clinic. There's no bleeding. There's very little risk for adverse event.
Almost everybody in the physician's office, whether the technician, a nurse practitioner, physician assistant, can do this treatment safely. A few words about the business model and the uniqueness of the business model for us. It starts with an upfront system purchase here in the U.S., where we sell direct to physicians. The MSRP for the SofWave system is $115,000. The device comes preloaded with 3,000 pulses. Pulses are clicks on the applicators, ultrasound beams that are being shot out of the applicator. 3,000 pulses are good for about 10 to 15 treatments. After that, the physicians, the customers need to come back to us and buy additional pulses in order to operate the device. Every treatment requires between 150 to 200 or 250 pulses, depends on the treated area and the size of the treated area.
Our price per pulse here in the U.S. is $1.50. It translates to about $225-$300 of every treatment that is being done by our physicians coming back to us. As I mentioned before, this is a very fast-growing utilization model. More than that, it's completely virtual, meaning, again, there's no physical consumables, so very high gross margin. Even more than that, they buy this consumable online with credit card. They can do it from the machine itself, from a computer, or even from an iPhone or Android app that we have. They put in their credit card and the pulses are being loaded automatically to the system, which means that we get the money almost upfront because most of the purchases are done by credit card. I said 47% of our revenue are coming from utilization.
It also means 47% coming almost on a completely cash basis. If you look at our DSO, it's under 30 days in the last quarter, which is very unusual for a capital equipment company. We designed our business model not only to work for us, but also to work for our physicians. We want our physicians to be successful because it's some kind of a partnership between them. If they are successful, they make money, they will recommend this device, they will do more treatments. That means more revenue for us. We built an attractive business model that allows them to pay back for the initial capital equipment purchase within four to six months. We protect the treatment price by having a minimum advertised price on our purchase agreement, and we enforce it. That creates a very significant ROI.
When we look at the ROI, because we know how many pulses our customers are buying from us, we see that the median ROI here in the U.S. for a clinic is 182% in the first year of purchase. That translates to making your money back in less than six months. In addition to the SofWave ultrasound device, we also launched last year the PureImpact VIP, which is the muscle stimulation, muscle activation device. This is part of the overall strategy to go after the GLP-1 patients. Almost every clinic in the U.S. sees some GLP-1 patients these days. We are giving the one platform full solutions for clinicians who see GLP-1 patients, because as we said, what do they need? They need skin tightening, and this is what we do with the ultrasound.
The other thing that they need is muscle strength, muscle toning, and this is what clinical proof and clinical evidence is in the core for everything that we do. Since we launched the product, we have done many clinical trials, got 12 FDA clearances, 14 clinical trials in over 600 studied patients. Got clearances that usually companies in aesthetic medicine do not go after. Usually, they get one clearance and start selling the device. We are going after the proof to show the clinical efficacy from a clinical research perspective, and we secured wide variety of skin laxity, eyebrow lift, arm lift, cellulite, acne scar treatment, all this through our investment in clinical trials, clinical data. A little bit about our brand, and I mentioned before why the brand leadership is so important for us, because we are also advertising and selling our device or our treatments to the patients.
We want the patient to demand and request this treatment from the physician. As of the third quarter, we have 58% of the share of voice in our category. We are up in the mention share that we have online. Our engagement continues to grow, grew 44%. Our brand sentiment grew up to 94% in the fourth quarter. This is the positive things that people are saying on the online versus the negative people are saying about you online. That is 94% positive. We have over 1.6 million followers on the different media, social media platforms. That is creating over 40% of our capital equipment sales are being actually generated by marketing leads. By building this brand, we sell more capital equipment, but we also created a demand for our treatment that is coming from the patient.
I mentioned before that we got the very first regulatory approval in China. This is very fresh from the end of September of this year. This is something we have been working on with a local company in China for the last four years, and required a large clinical trial, almost 200 patients. It was performed and conducted by the local Chinese company called HBPK. I will tell you a little bit more about HBPK in the fourth slide. This is a very unusual kind of clinical trial. You see in aesthetic, close to 200 patients in five different hospitals, with top KOLs, peer opinions, leaders. What happened here, we got such great results.
First of all, we supported the NMPA approval, but we also have local clinical proof that now customers, physicians, can market to their patients in terms of the clinical proof in the Chinese market locally. Beside of that, I do not need to tell you how big the Chinese market is and how big the opportunity is on the capital equipment as well as the utilization. Again, we are going to make money from every pulse shot in the system, every treatment that is being done by the system. Few words about our distributor in China. HBPK is an experienced company, over 100-year-old company in China, owned by Warburg Pincus, large American private equity. They are a large company that sells medical devices and medical institutions in China. They have over 10,000 medical institutions that they sell to, over 3,000 support over 50 brands. They really took SofWave.
SofWave is going to be their first and most unique aesthetic device. They do not sell any other aesthetic device. They actually set a subsidiary just for the aesthetic space and appointed Peter Lyu as the CEO. Peter Lyu is a veteran in the aesthetic space in China, ex-Solta and ex-Fotona. So we have a dedicated partner that not only funded and worked very hard on the clinical trial and the regulatory approval in China, but is also preparing themselves for the launch and marketing the product in the Chinese market. We just mentioned that together with the approval, we got an open order for 70 devices, which 10 out of them were delivered in the third quarter, and 60 systems are projected to be delivered in the fourth quarter of the year.
A little bit about our progress and priorities for the second half and the fourth quarter of the year. Obviously, we are growing here in the U.S. We are adding sales reps. We want to increase our coverage and increase the productivity of the sales team. We are working hard with our sales and marketing team for the preparation for the Chinese launch. We scale internationally. For the first time, international market outpaced or grew more than the U.S. market. 51% of the revenue today comes from outside of the U.S., which is very important in terms of diversification of revenue and the geographical expansion. Expanding our marketing age, and as I said, we are working on what is next. We are working on the next platform that we will be able to share more information about in the future. We are expanding to what we call total body.
When we launched the SofWave device, we remained focused on the face and the neck in terms of skin tightening. During the years, we received clinical clearances for treatments of the body. We launched the liftHD applicator, which is a dedicated applicator, larger applicator for body treatment. What it means is that we started to see clinicians moving to treat patients, moving from the face and the neck, moving to the body. Obviously, the body has larger coverage area that will require more pulses, and eventually drive higher utilization and higher profit. Back a little bit down into the Q3 numbers and our revenue. If you look to the top 10 slides, you see our Q3 revenue all the way from 2021, going from $2.8 million in 2021. It is funny, again, 10x.
10X.
Still 10x until now. Year-over-year, you always look, "Okay, what did you do in 2025?" Then you zoom out a little bit and say, "That is 10x from 2021." It is very exciting. It was 35%, and annually, we finished last year with $87.6 million in revenue. If you look at the orange part of the bar, this is the part of the bar that is representing the recurrent revenue. You see how the orange portion of the graph in the revenue continues to grow, and that is an annual curve of 42% since 2021. Here is a nice realization of every quarter, Q1, two, three, and four, all the way from 2022. We see a nice growth in each one of these, but you really see an acceleration in growth in 2025, and we continue to do in 2026.
This thanks to everything I just talked about, the GLP-1 phenomena, the [nanocap, the additional applications, and clinical really kind of injecting the accelerating our growth. What is interesting to see, the $28.5 million in the third quarter is almost what we sold in the fourth quarter of 2025. The fourth quarter in the aesthetic space is the strongest quarter by far. The third quarter is by retail sales. We almost sold the same dollars in the third quarter of 2026 as in the fourth quarter of last year. We still have the fourth quarter of 2026, which is considered to be the strongest quarter of the year. I talked a little bit about our geographical split, about 50% of the revenue are here in the U.S. and Canada. 37% are coming from Asia. Asia is growing very fast. We are doing very well in Korea.
Korea is considered to be a very good market for aesthetics. There are many, many different brands. There is a huge awareness with Korean patients for aesthetics. We saw success in the market of Korea. It is very encouraging in terms of our ability to continue and succeed in other places in Asia, because China, I would mention that in April of last year, we also received a regulatory approval in Japan, and we have a very strong distribution in Japan as well. Looking at all this, it is great, but I will also mention that we sell in approximately 60 countries right now. There is still a lot of room for geographical expansion as well. We do not do almost any business in Brazil.
We have few key markets in Europe that we do not have business in right now, such as Italy, Germany, Switzerland, Austria, and we are just starting in China. So there is still a lot of room for geographical expansion. Many times we see growth trajectory in revenue, but it does not necessarily come from profitability. We see consistent increase in our profit. This is a graph of our non-IFRS excluding stock-based compensation of our quarterly operating loss. It became very profitable with the all-time high operating and net income, and operating income of $4.9 million in the third quarter against the slowest quarter of the year in aesthetics. Looking a little bit about on our Q3 P&L, I mentioned before that we have a very healthy strong gross margin, but we also have significant leverage on our operating expenses.
R&D expenses and our G&A expenses do not grow as revenue continues to grow, or grow at the same pace of revenue. Our sales and marketing as a percentage of revenue continues to decline. Only a few years ago, sales and marketing were 70% of revenue, went down to 60%, to 50%, to low 40s, hit 39% in the third quarter of this year. That is all supporting. The overall operating expense went down from 65% last year to 59% in Q3 of this year. Our non-IFRS operating income grew by 161% to 17% of revenue. The non-IFRS net income increased by $275 from $1.4 million last year to $4.6 million in the third quarter of 2026. When we look at the year-to-date numbers, we see a similar picture.
We get a very healthy gross margin, reduction in percentage of operating expenses as a percentage of revenue. Operating income increased by 145%. Non-IFRS net income increased by 184% and hit 12% of our revenue in the first nine months of the year. A few words about our balance sheet, a very healthy balance sheet, no debt, $41.4 million in cash. We have been generating cash. We generated $2.6 million in the third quarter. We can see that our inventory is growing. We are building inventory to continue and support our growth and specifically our launch in China. We are investing in working capital, still generating significant amount of cash. Again, $41.4 million cash and no debt on the balance sheet. To summarize it, John, we have a profitable, high-growth company, 35% growth in the third quarter.
47% of the revenue comes from the utilization of the device. With this partnership, every device that we sell is a partnership with a clinic. We actually do not sell a device turning our back to the customer. We are selling a device and starting a partnership with the customer. We need the customer to be successful to launch the device, to increase utilization, because we enjoy their profits and their revenue from the device as well. We crossed the 1 million treatment milestone, which is a really important milestone for us. We are getting ready for the market opportunity.
Okay. That was great. That was fantastic. Thank you. Maybe I will just start with a couple questions. Guys, if you have any questions, let me know. Just talk to us about the overall environment for capital. It is obviously a choppy stock market, but I am curious what you are seeing for capital. I think you said in the most recent quarter was up 19%. That was with very little China. What is the environment like out there, and how are you selling this to these guys? In other words, are they paying cash? Are they accessing credit? We have heard that can be getting a little bit more difficult. Maybe some color there.
Yeah. Great question. First of all, because of our business model, it is combining capital equipment and then the utilization, we charge a little bit less on the capital. Our average selling price in the U.S. is under $100,000.
Okay.
Which make it more easier to finance, first of all. It is easier to get credit for under $100,000 than over $100,000. Second of all, the increase in interest rate that we have seen over the last years, less affecting when you buy less expensive capital.
Sure.
In addition to that, I will say that we are still in the early stages of penetration in the U.S. and internationally. We reported that we sold 3,400 SofWave systems, and we can estimate that less than half of them are in the U.S. When you think about the number of dermatologists and plastic surgeons here in the U.S., you are probably talking about 16,000, 17,000 docs. When you are looking for the medical spas in the U.S., easily over 10,000 docs. So you are talking about probably in the U.S., 30,000, and they are being conservative here globally, probably double that, and it is still a conservative assumption. So we are very early on in our penetration. We are still growing our system in order to increase coverage. Yes, it has been choppy for credit, and many of our customers are choosing to pay cash.
When you go after the core physicians, the dermatologists and the plastic surgeons, and they see the ROI profile of that device-
They can afford putting $90,000 or $100,000 on the black American Express card. They can do that. If you look at our P&L, one P&L item, one expense item continue to grow is credit card fees. When I joined the company, I never thought about capital equipment company, credit card fees. Will never be significant. We are actually working very hard to decrease our percentage of fees right now, because we see more and more customers paying by credit card. As I said before, the pulses are mostly sold by credit card.
Right.
low DSOs and less effect of interest rate because of the price point of our capital.
How do we think about recurring longer term? 47% of revenue, where can that go, and do we just continue with that natural margin expansion that accompanies it because of the near 100% GM on the consumable?
We like the split of being a little bit under 50%, but around 50%, 50/50.
You don't want it to go too far because then the capital slows down.
Because then the capital, that makes the capital. I just described in length
Yeah
how much more opportunity we have with capital. We are expecting to see the capital growing. Obviously, the utilization growing faster, but it is still, we like the 50/50. Thinking about China and the additional geographical expansion, we think that 50/50, a little bit under 50% utilization is what we are going to see in the next year.
The IFRS, I think it was EBIT margin of 17%, so EBITDA probably close to 20. Is this a 25%, 30% EBITDA business longer term?
Longer term, yes.
Okay.
This guidance, long-term projection, let's say, we can do the math. No reason not to.
Help us with China. I mean, I am sure that was an initiative for a while. Congratulations. You got the approval. Some boxes went out in 3Q, more will go out in 4Q. How do you know you have the right partner, one, and then is there a way to roughly size the opportunity for you guys longer term?
We chose this partner four years ago, which we signed the agreement with them in 2022, understanding that they would take upon themselves to get the regulatory approval. We know that we got the right partner, first of all, because they got the approval.
Yeah.
The approval required a large clinical trial, expensive clinical trial, and they supported it, they funded it, and they got it. In addition to that, they discussed on how much they already started to put into the sales and marketing infrastructure, and they built a special force just for us right now, for our equipment. We feel very comfortable with the partner. Obviously, there is a lot of work to be done here. It is not an immediate ramp-up, and it is not going to be a huge market overnight. But long term, we think in terms of number of systems, it can be similar to the size of number of systems sold in the U.S.
Okay. And maybe last one for me as we sort of count down, but that geographic pie chart that you threw out there, it seems like there is still some room to run in APAC, right? You mentioned the recent Japan approval, China, very aesthetic markets within APAC, that that could be a significant contributor longer term.
It is a big market, growing faster than any other market in the world.
Okay. Any last-minute questions? SofWave, thanks very much. Appreciate it.